Henrik Blou, Gubra CEO
November 13, 2024 02:27 PM EST
R&D

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Kyle LaHucik

Senior Reporter

The amylin field is heat­ing up ahead of No­vo Nordisk’s much-an­tic­i­pat­ed Ca­griSe­ma read­out lat­er this year.

On Wednes­day, Gubra said peo­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times